Clinical Trials

Inovio Pharmaceuticals, Inc announced that post-hoc analysis of data generated from its phase 2b trial of VGX-3100 identified immune correlates and biomarker signatures predictive of treatment success. VGX-3100, Inovio’s lead product now in a pivotal phase...

OSE Immunotherapeutics announces that the Independent Data Monitoring Committee (IDMC) has recommended to the trial’s steering committee that accrual of the Tedopi® Phase 3 trial for the treatment of advanced non-small cell lung cancer (NSCLC) could resume with a...

CRF Health, the leading global provider of patient-centered eSource technology and service solutions for the life sciences industry, has been selected by a leading specialty pharmaceutical company for its latest pediatric rare disease Phase II study. ...

Cmed, an oncology focused, innovative technology-led CRO, announced that it will showcase its encapsia® clinical data suite at two leading oncology meetings, Clinical Operations in Oncology Trials Europe, taking place 5-6 December in Munich, Germany, and the ASH Annual...

The average cost of bringing a new drug to market is $2.6 billion, according to a 2014 report published by Tufts Center for the Study of Drug Development. This is a rise of 145%, adjusted for inflation, compared to just...

Cmed, an innovative technology-led CRO, will demonstrate its encapsia® clinical data suite at Partnerships in Clinical Trials Europe, taking place 28-29 November 2017 in Amsterdam, The Netherlands. Currently used in trials with nine Pharma companies, including...

Biotechnology and pharmaceutical companies within the United States and Europe face an increasing number of hurdles when undertaking clinical trials within their own country or region; problems such as over saturated patient pools, difficulties meeting and maintaining enrollment numbers, increasing costs and lengthy time delays. While clinical trials...